A major international study published in the Journal of Thoracic Oncology reveals that specific genetic mutations in mesothelioma tumors significantly influence patient survival and, when combined with traditional staging, can improve the accuracy of survival predictions. This new information may impact how doctors predict outcomes and create treatment plans for the rare, asbestos-related cancer.
Molecular Alterations in Mesothelioma Provide New Prognostic Information
The study analyzed the cases of 556 mesothelioma patients diagnosed between 2013 and 2022 from three major cancer centers participating in the International Association for the Study of Lung Cancer staging project. Researchers combined next-generation sequencing data with clinical information and immunohistochemistry results to explore whether molecular alterations in patients’ cells could provide additional information when combined with traditional staging.
Predicting mesothelioma outcomes has historically relied on tumor stage, histologic subtype (epithelioid versus sarcomatoid), and patients’ overall health. Patients with epithelioid mesothelioma tumors and earlier-stage disease generally have the most favorable outcomes, while non-epithelioid histologies are associated with worse survival. Because outcomes vary widely, even among patients diagnosed at the same stage and with the same histology, scientists have looked to genomic biomarkers to help refine prognostic accuracy.
Improved Mesothelioma Survival Predictions Rely on Next-Generation Genetic Sequencing
Next-generation sequencing was performed on 260 mesothelioma tumors to determine how often key genetic events occurred. The most common genomic alterations were BAP1 mutations (55.0%), CDKN2A alterations (36.2%), NF2 alterations (23.8%), TP53 alterations (18.1%), and SETD2 alterations (8.8%), which confirmed that, rather than genetic mutations, tumor suppressor gene disruption is what largely drives mesothelioma biology
The researchers found that several specific molecular alterations were strongly associated with overall mesothelioma survival. Genomic alterations linked to worse survival included CDKN2A mutations, NF2 mutations, and TP53 mutations. Conversely, BAP1 alterations were associated with better mesothelioma survival. After adjusting for clinical factors, the study concluded that CDKN2A loss may be one of the strongest molecular predictors of poor survival in mesothelioma.
Combined Analysis Provides More Accurate Mesothelioma Survival Predictions
The mesothelioma researchers found that clinical factors alone produced moderate predictive performance, and genomic biomarkers alone were slightly less predictive, but by combining both clinical and molecular features, predictive performance improved substantially. This shows that mesothelioma’s molecular alterations provide complementary prognostic information beyond TNM staging alone. While traditional staging remains essential, genomic biomarkers may help refine prognostic stratification, guide treatment selection, improve pathology reporting, and inform future staging systems.
If you or someone you love has been diagnosed with mesothelioma, having a clear sense of what lies ahead makes a real difference. For more information on the resources available to you, contact the Patient Advocates at Mesothelioma.net today at 1-800-692-8608.
